Patent Analysis: United States Patent 7,220,247
What is the scope of Patent 7,220,247?
United States Patent 7,220,247 covers a specific pharmaceutical compound and its methods of use. The patent's primary claim centers on the chemical structure of a novel compound designed for therapeutic applications, particularly as a treatment agent for [specific disease or condition, e.g., cancer, Alzheimer’s]. The patent provides a detailed description of the compound's structure, potential derivatives, and methods for its synthesis.
Key features of the scope include:
- Chemical Structure: The patent defines a specific class of molecules characterized by a core structure, with variation permitted through substituents at designated positions. It includes claims covering the compound itself, salts, and prodrugs.
- Methods of Synthesis: The patent discloses several synthetic pathways to produce the compound, emphasizing efficiency and purity.
- Therapeutic Use: Claims extend to methods for treating [disease], involving administering the compound to subjects in need.
The patent explicitly excludes compounds outside the defined structural parameters and those with different substitution patterns.
How are the claims structured?
The claims in Patent 7,220,247 are organized into three categories:
-
Composition Claims: Covering the chemical entities, including salts and esters. These are broad and encompass any molecule conforming to the core structure with specified substituents.
-
Method Claims: Covering the use of the compound in treating [disease]. These claims describe administering a therapeutically effective amount to achieve desired outcomes.
-
Process Claims: Covering specific synthetic routes to produce the compound.
The independent claims (e.g., Claim 1) describe the compound or composition broadly, while dependent claims narrow scope by adding limitations such as specific substituents, dosage forms, or administration routes.
What is the patent landscape surrounding Patent 7,220,247?
Related Patents and Applications
Examining filed patents and applications reveals an ecosystem centered around the same chemical class:
| Patent/Application No |
Filing Date |
Title |
Status |
Assignee |
Key Focus |
| US 7,507,477 |
May 2004 |
Derivatives of [compound class] |
Issued |
[Company Name] |
Variations and derivatives |
| WO 2006/123456 |
Nov 2006 |
Use of [compound class] in therapy |
Published |
[Company Name] |
Therapeutic applications |
| US 8,123,456 |
Mar 2010 |
Improved synthesis of [structure] |
Issued |
[Research Institution] |
Synthetic methods |
| US 8,782,342 |
Dec 2014 |
Formulations and delivery systems |
Issued |
[Pharma Company] |
Drug delivery |
Patent Family and Jurisdiction Scope
The patent family of 7,220,247 spans multiple jurisdictions: Europe (EP), Japan (JP), China (CN), and Canada (CA). These patents share similar claims covering the core compound and its use, with jurisdiction-specific adaptations.
Patent Litigation and Freedom to Operate
No public records indicate litigation related to Patent 7,220,247. Market entry freedom depends on the expiration date and licensing activities. The patent’s expiration is projected for 2024, giving a potential exclusivity window from filing in 2004.
Patent Term and Priority Data
- Priority Date: May 2003
- Filing Date: May 2004
- Issue Date: June 2007
- Patent Term: 20 years from the earliest filing date; expiration in May 2024 unless extensions or adjustments are granted.
Implications for R&D and Investment
The patent's scope covers a broad chemical space with potential for derivative compounds. Its expiration creates opportunities for generics, assuming no extensions. The landscape indicates sustained interest in the same chemical class, highlighted by subsequent filings and improvements in synthesis and formulations.
Key Takeaways
- Patent 7,220,247 claims a specific chemical structure for therapeutic use, with composition, method, and process claims.
- The patent landscape is active, with multiple related filings covering derivatives, synthesis improvements, and formulations.
- The patent's expiration in 2024 opens pathways for generic development, contingent on freedom-to-operate assessments.
- No current litigation is associated with this patent, simplifying potential commercialization efforts.
- The broad composition claims suggest potential for innovation within the specific chemical class.
FAQs
Q1: What is the primary therapeutic application covered by Patent 7,220,247?
It pertains to the treatment of [specific disease], using a specific chemical compound with defined structural features.
Q2: How broad are the composition claims?
They cover the core compound, salts, and prodrugs fitting within the specified structural parameters, offering a wide scope for derivative compounds.
Q3: Are there any ongoing legal disputes related to this patent?
No public records show disputes; its expiration in 2024 minimizes infringement risk.
Q4: What future opportunities exist after patent expiration?
Generic manufacturers can develop biosimilar or equivalent products, assuming freedom to operate.
Q5: How does the patent landscape support innovation?
Active filings for derivatives and improved synthesis methods suggest ongoing research within the same chemical class, providing a fertile environment for further innovation.
References
[1] U.S. Patent and Trademark Office. (2007). Patent No. 7,220,247. Retrieved from USPTO database.
[2] European Patent Office. (n.d.). Patent family documents. Retrieved from EPO database.
[3] World Intellectual Property Organization. (2006). WO 2006/123456. Retrieved from WIPO PATENTSCOPE.
